Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki

Mol Psychiatry. 2022 Sep;27(9):3563-3564. doi: 10.1038/s41380-022-01546-2. Epub 2022 Apr 6.

Authors

Yaeko Hashimoto^{1

2}, Takuji Suzuki¹, Kenji Hashimoto³

Affiliations

¹ Department of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
² Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan.
³ Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan. hashimoto@faculty.chiba-u.jp.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Fluvoxamine / therapeutic use
Humans
Post-Acute COVID-19 Syndrome
Receptors, sigma*
Sigma-1 Receptor

Substances

Fluvoxamine
Receptors, sigma